Rhythm Pharmaceuticals 将来の成長

Future 基準チェック /56

Rhythm Pharmaceuticals利益と収益がそれぞれ年間58.5%と40.3%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-100.7% 58.6%なると予測されています。

主要情報

58.5%

収益成長率

58.6%

EPS成長率

Biotechs 収益成長	35.0%
収益成長率	40.3%
将来の株主資本利益率	-100.7%
アナリストカバレッジ	Good
最終更新日	31 Dec 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:1RV - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2027	603	169	26	330	7
12/31/2026	321	-62	-89	43	9
12/31/2025	180	-167	-169	-76	12
12/31/2024	124	-265	-267	-127	12
9/30/2024	113	-262	-165	-124	N/A
6/30/2024	102	-261	-169	-128	N/A
3/31/2024	92	-274	-182	-140	N/A
12/31/2023	77	-185	-142	-136	N/A
9/30/2023	62	-186	-146	-141	N/A
6/30/2023	44	-182	-164	-159	N/A
3/31/2023	34	-181	-161	-156	N/A
12/31/2022	24	-181	-174	-173	N/A
9/30/2022	17	-181	-173	-180	N/A
6/30/2022	13	-176	-166	-173	N/A
3/31/2022	5	-166	-160	-166	N/A
12/31/2021	3	-70	-139	-146	N/A
9/30/2021	1	-62	-135	-135	N/A
6/30/2021	0	-60	-122	-122	N/A
3/31/2021	0	-56	-120	-119	N/A
12/31/2020	N/A	-134	-122	-122	N/A
9/30/2020	N/A	-132	-125	-125	N/A
6/30/2020	N/A	-134	-132	-132	N/A
3/31/2020	N/A	-146	-130	-127	N/A
12/31/2019	N/A	-141	-126	-123	N/A
9/30/2019	N/A	-133	-115	-112	N/A
6/30/2019	N/A	-115	-99	-95	N/A
3/31/2019	N/A	-87	-83	-82	N/A
12/31/2018	N/A	-74	-63	-62	N/A
9/30/2018	N/A	-59	-49	-49	N/A
6/30/2018	N/A	-53	N/A	-40	N/A
3/31/2018	N/A	-47	N/A	-34	N/A
12/31/2017	N/A	-38	N/A	-29	N/A
9/30/2017	N/A	-36	N/A	-28	N/A
6/30/2017	N/A	-32	N/A	-24	N/A
3/31/2017	N/A	-30	N/A	-24	N/A
12/31/2016	N/A	-29	N/A	-23	N/A
9/30/2016	N/A	-27	N/A	-21	N/A
6/30/2016	N/A	-23	N/A	-18	N/A
3/31/2016	N/A	-17	N/A	-13	N/A
12/31/2015	N/A	-12	N/A	-7	N/A
9/30/2015	N/A	-6	N/A	-4	N/A
6/30/2015	N/A	-3	N/A	-4	N/A
3/31/2015	N/A	-5	N/A	-6	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 1RVは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 1% ) よりも高い成長率であると考えられます。

収益対市場: 1RV今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: 1RV今後 3 年以内に収益を上げることが予想されます。

収益対市場: 1RVの収益 ( 40.3% ) German市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: 1RVの収益 ( 40.3% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 1RV 3 年以内に赤字になると予測されています。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/01/06 06:52
終値	2025/01/06 00:00
収益	2024/09/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Rhythm Pharmaceuticals, Inc. 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。18

アナリスト	機関
Tazeen Ahmad	BofA Global Research
Whitney Ijem	Canaccord Genuity
Corinne Johnson	Goldman Sachs

Rhythm Pharmaceuticals 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Forecast to breakeven in 2026

No longer forecast to breakeven

Forecast to breakeven in 2026

Forecast to breakeven in 2024

Recent updates

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (Setmelanotide) for Patients as Young as 2 Years Old

Rhythm Pharmaceuticals Announces IMCIVREE (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, Including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in the Lancet Diabetes & Endocrinology

Third quarter 2024 earnings released: US$0.73 loss per share (vs US$0.76 loss in 3Q 2023)

Rhythm Pharmaceuticals Announces Five New Data Presentations At Obesityweek 2024

Rhythm Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for Imcivree® (Setmelanotide) in Patients as Young as 2 Years Old

Second quarter 2024 earnings released: US$0.55 loss per share (vs US$0.82 loss in 2Q 2023)

Forecast to breakeven in 2026

Rhythm Pharmaceuticals, Inc. Announces European Commission Expands IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

Rhythm Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Rhythm Pharmaceuticals, Inc. Announces Appointment of Alastair Garfield, as Chief Scientific Officer

Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Index

Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients Between 2 and 6 Years Old with Bardet Biedl Syndrome

New minor risk - Profitability

No longer forecast to breakeven

Rhythm Pharmaceuticals, Inc. Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

First quarter 2024 earnings released: US$2.35 loss per share (vs US$0.92 loss in 1Q 2023)

Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology

Rhythm Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024

Rhythm Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

New major risk - Financial position

Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management

Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

Perceptive Advisors Engages in Discussion with Rhythm Pharmaceuticals

Full year 2023 earnings released: US$3.20 loss per share (vs US$3.48 loss in FY 2022)

Rhythm Pharmaceuticals, Inc. Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

New minor risk - Profitability

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024

New major risk - Share price stability

Forecast to breakeven in 2026

Third quarter 2023 earnings released: US$0.76 loss per share (vs US$0.80 loss in 3Q 2022)

Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)

Rhythm Pharmaceuticals, Inc. Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome

Second quarter 2023 earnings released: US$0.82 loss per share (vs US$0.89 loss in 2Q 2022)

Rhythm Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Rhythm Pharmaceuticals, Inc. Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023

Rhythm Pharmaceuticals, Inc. Announces Approval of IMCIVREE®? Setmelanotide Solution for Weight Management in Adult and Pediatric Patients

First quarter 2023 earnings released: US$0.92 loss per share (vs US$1.05 loss in 1Q 2022)

Full year 2022 earnings released: US$3.48 loss per share (vs US$1.40 loss in FY 2021)

Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Announces ?Imcivree (Setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Third quarter 2022 earnings released: US$0.80 loss per share (vs US$0.70 loss in 3Q 2021)

Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology

Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-Term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity At Obesityweek® and Plans to Initiate Phase 3 Trial in Early 2023

Rhythm Pharmaceuticals, Inc. Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA

Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

Rhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022

Rhythm Pharmaceuticals, Inc. Announces European Commission Expands the Marketing Authorization for Imcivree(R) (Setmelanotide)

Second quarter 2022 earnings released: US$0.89 loss per share (vs US$0.70 loss in 2Q 2021)

Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France

NICE Recommends Rhythm’s IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency

Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc. Announces That European Commission Authorized Variation for Imcivree (Setmelanotide) to Allow for Dosing in Patients with POMC or LEPR Deficiency with Renal Impairment

Rhythm Pharmaceuticals, Inc. Announces FDA Approval of IMCIVREE for Use in Patients with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Presents Initial Data from Long-Term Extension Trial Evaluating Setmelanotide in Rare Genetic Diseases of Obesity at ENDO 2022

Rhythm Pharmaceuticals, Inc. Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome At the Pediatric Endocrine Society 2022 Virtual Annual Meeting

Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity

Forecast to breakeven in 2024

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome

Rhythm Pharmaceuticals, Inc. Announces Executive Promotions

Rhythm Pharmaceuticals, Inc. Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS)

Rhythm Pharmaceuticals, Inc. Announces Dosing Initiated in Phase 3 Trial of Weekly Setmelanotide in Patients with Genetic Obesity Disorder

High number of new directors

Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE® (setmelanotide) in Great Britain

Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl and Alström Syndromes

Chief Medical Officer Murray Stewart has left the company